[Injectable hospital preparation of valine labeled with the carbon 13 and nitrogen 15 (5 mg/mL) for a clinical trial on the brain tumor metabolism: Pharmaceutical control of active pharmaceutical ingredient and stability study of the finished product]

Ann Pharm Fr. 2015 Sep;73(5):361-77. doi: 10.1016/j.pharma.2015.02.002. Epub 2015 Mar 5.
[Article in French]

Abstract

Introduction: The L-Valine labeled (L-[U-(13)C,(15)N] Val) is a stable isotopic tracer administered by parenteral route within the framework of a new clinical research program concerning the brain tumor metabolism. To meet regulatory requirements and have ready to use solution with an expiration date, a pharmaceutical control of active pharmaceutical ingredient followed by stability study of hospital preparation were realised.

Materials and methods: After the pharmaceutical control of the L-[U-(13)C,(15)N] Val, the hospital preparation was prepared according to the good manufacturing preparation. Prepared bottles were stored at 5°C±3°C and 25°C±2°C for six months. The stability of the preparation was determined by physico-chemical controls (pH, osmolality, sub-visible particles, L-[U-(13)C,(15)N] Val concentration, sodium concentration, isotopic enrichment) and microbiological (bacterial endotoxin and sterility).

Results: Concentrations of L-[U-(13)C, (15)N] Val and sodium does not significantly decrease during the stability study. In parallel, no change in pH and osmolality were highlighted. Isotopic enrichment higher than 99.9% reflected the stability of labeling of L-valine molecule. The sub-visible particles, the bacterial endotoxin and sterility were in accordance with the European Pharmacopoeia attesting limpidity, apyrogenicity and sterility of this injectable preparation.

Discussion and conclusion: The stability of this hospital preparation of L-[U-(13)C, (15)N] Val has been demonstrated for six months at 5°C±3°C and 25°C±2°C, ensuring a parenteral administration as part of the clinical trial.

Keywords: Active pharmaceutical ingredient; Brain tumor; Clinical research; Contrôle pharmaceutique; Finished product; Glioblastome; Hospital preparation; Isotope stable; L-valine labeled; L-valine marquée; Métabolisme tumoral; Pharmaceutical control; Produit fini; Préparation hospitalière; Recherche clinique; Stability; Stabilité; Stable isotope; Substance active.

MeSH terms

  • Brain Neoplasms / metabolism*
  • Carbon Isotopes
  • Drug Compounding
  • Drug Stability
  • Injections
  • Isotope Labeling
  • Nitrogen Isotopes
  • Pharmaceutical Solutions
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / chemistry*
  • Radiopharmaceuticals / pharmacokinetics*
  • Reproducibility of Results
  • Valine / administration & dosage
  • Valine / chemistry*
  • Valine / pharmacokinetics*

Substances

  • Carbon Isotopes
  • Nitrogen Isotopes
  • Pharmaceutical Solutions
  • Radiopharmaceuticals
  • Valine